Table 2.
Patient and tumor characteristics
| Characteristics | Statin users (N = 171)1 | Nonusers (N = 538) | P |
|---|---|---|---|
| Gender, N (%) | |||
| Male | 100 (58.5) | 268 (49.8) | 0.05 |
| Female | 71 (41.5) | 270 (50.2) | |
| Age2 (year) | |||
| Mean (SD) | 67.3 (11.7) | 58.0 (16.5) | <0.001 |
| Median (IQR) | 70 (60–77) | 59 (46–70) | |
| Time of FU | |||
| Years, median (IQR) | 3.5 (1.6–5.8) | 2.9 (1.3–5.3) | 0.02 |
| Number of deaths N (%) | 40 (23.4) | 119 (22.1) | 0.73 |
| Histological subtype, N (%) | |||
| SSM | 91 (53.2) | 257 (47.8) | 0.09 |
| NMM | 30 (17.5) | 147 (27.3) | |
| LMM | 4 (2.3) | 8 (1.5) | |
| ALM | 2 (1.2) | 5 (0.9) | |
| Others | 44 (25.7) | 121 (22.5) | |
| Body site of the melanoma, N (%) | |||
| Head and neck | 30 (17.5) | 81 (15.1) | 0.36 |
| Trunk | 65 (38.0) | 191 (35.5) | |
| Upper extremity | 37 (21.6) | 106 (19.7) | |
| Lower extremity | 39 (22.8) | 160 (29.7) | |
| Tumor thickness, N (%) | |||
| ≥1.01 and ≤2 | 83 (48.5) | 287 (53.3) | 0.39 |
| ≥2.01 and ≤ | 60 (35.1) | 159 (29.6) | |
| ≥4.01 | 28 (16.4) | 92 (17.1) | |
| Nodal metastases,2 N (%) | 26 (15.2) | 78 (14.5) | 0.82 |
| Distant metastases,2 N (%) | 3 (1.8) | 12 (2.2) | 1.00 |
| Comorbidities,2 N (%) | |||
| Any | 105 (61.4) | 162 (30.1) | <0.001 |
| Hypertension | 46 (26.9) | 69 (12.8) | <0.001 |
| Heart diseases | 58 (33.9) | 39 (7.2) | <0.001 |
| Cancer | 32 (18.7) | 57 (10.6) | 0.01 |
| Stroke | 11 (6.4) | 7 (1.3) | <0.001 |
| Diabetes | 22 (12.9) | 20 (3.7) | <0.001 |
| Lung diseases | 10 (5.8) | 24 (4.5) | 0.22 |
| Gastrointestinal diseases | 8 (4.7) | 7 (1.3) | 0.01 |
| Unique hospitalizations,3 N (%) | |||
| No admissions | 130 (76.0) | 464 (86.2) | 0.01 |
| 1 admission | 31 (18.1) | 55 (10.2) | |
| >1 admission | 10 (5.8) | 19 (3.5) | |
| Unique ATC codes,3 N (%) | |||
| 0 ATC codes | 11 (6.4) | 100 (18.6) | <0.001 |
| 1–3 ATC codes | 36 (21.4) | 240 (44.6) | |
| >3 ATC codes | 124 (72.5) | 198 (36.8) | |
| Average DDD, mean (SD) | 0.97 (0.55) | n.a. | n.a. |
| Average statin exposure in days, mean (SD) | 959.8 (882.0) | n.a. | n.a. |
ATC, anatomical therapeutic chemical classification system; FU, follow-up; IQR, interquartile range; N, total number of patients.
1
Statin user after melanoma diagnosis.
2
At the time of initial melanoma diagnosis.
3
In the year prior to diagnosis.